STOCK TITAN

Ginkgo Bioworks (DNA) CFO logs 743 RSU vesting, tax sale

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. (DNA) reported insider equity activity by Chief Financial Officer Steven P. Coen. On August 21, 2026, 743 Restricted Stock Units vested and were converted into an equal number of Class A Common shares in two tranches of 587 and 156 RSUs. On August 24, 2026, Coen sold 330 shares of Class A Common Stock at $6.977 per share to cover tax withholding obligations related to vesting; the company states these sell-to-cover trades were not discretionary. The Rule 10b5-1 trading plan checkbox was not selected.

Positive

  • None.

Negative

  • None.
Insider Coen Steven P.
Role See remarks
Sold 330 shs ($2K)
Approx. gross sale proceeds $2K
Type Security Shares Price Value
Sale Class A Common Stock F2 330 $6.977 $2K
Exercise Restricted Stock Units F1, F3 587 -- --
Exercise Restricted Stock Units F1, F4 156 -- --
Exercise Class A Common Stock F1 587 -- --
Exercise Class A Common Stock F1 156 -- --
Holdings After Transaction: Restricted Stock Units — 8,271 shares (Direct); Class A Common Stock — 51,851 shares (Direct)
Footnotes (4)
  1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
  2. F2. Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
  3. F3. The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.
  4. F4. The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.
Shares sold 330 shares Class A Common Stock sale on August 24, 2026 to cover tax withholding
Sale price per share $6.977 per share Price for 330 Class A Common shares sold on August 24, 2026
RSUs converted (total) 743 RSUs Total Restricted Stock Units converted into Class A Common Stock on August 21, 2026
RSUs tranche 1 587 RSUs First RSU tranche converted into Class A Common Stock on August 21, 2026
RSUs tranche 2 156 RSUs Second RSU tranche converted into Class A Common Stock on August 21, 2026
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
sell to cover financial
"plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
tax withholding obligations financial
"Represents shares sold ... to cover tax withholding obligations in connection with the vesting"
equity incentive plans financial
"The Issuer's equity incentive plans allow the Issuer to require that satisfaction"
Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

FAQ

What insider transactions did DNA’s CFO Steven P. Coen report?

Steven P. Coen reported that 743 RSUs vested and were converted into Class A Common Stock on August 21, 2026, and that he sold 330 shares of Class A Common Stock on August 24, 2026, to cover tax withholding obligations related to vesting.

How many Ginkgo Bioworks (DNA) shares did the CFO sell and at what price?

The CFO sold 330 shares of Ginkgo Bioworks Class A Common Stock at a price of $6.977 per share on August 24, 2026. The company explains these shares were sold to cover tax withholding obligations from equity vesting.

Were the recent DNA insider sales by the CFO discretionary trades?

No. The filing states the 330 shares sold on August 24, 2026 were sold to cover tax withholding obligations arising from restricted stock and/or RSU vesting and that such sell-to-cover sales do not represent discretionary trades by the reporting person.

What equity awards vested for DNA’s CFO in August 2026?

On August 21, 2026, 743 Restricted Stock Units held by the CFO vested and were converted into an equal number of Ginkgo Bioworks Class A Common shares, in two tranches of 587 RSUs and 156 RSUs, each corresponding to one share of stock per RSU.

Were DNA CFO’s August 2026 transactions under a Rule 10b5-1 plan?

The document-level Rule 10b5-1 checkbox is not selected, indicating these August 2026 transactions were not affirmatively reported as being made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Coen Steven P.

(Last)(First)(Middle)
C/O GINKGO BIOWORKS HOLDINGS, INC.
27 DRYDOCK AVENUE

(Street)
BOSTON MASSACHUSETTS 02210

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock08/21/2026M(1)587A(1)52,025D
Class A Common Stock08/21/2026M(1)156A(1)52,181D
Class A Common Stock08/24/2026S(2)330D$6.97751,851D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)08/21/2026M(1)587 (3) (3)Class A Common Stock587(1)5,296D
Restricted Stock Units(1)08/21/2026M(1)156 (4) (4)Class A Common Stock156(1)2,975D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
2. Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
3. The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.
4. The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.
Remarks:
Chief Financial Officer
/s/ Karen Tepichin, Attorney-in-Fact08/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)